No Panel Needed To Expand Impella Into Cardiogenic Shock, Abiomed Says
This article was originally published in The Gray Sheet
Executive Summary
Abiomed and FDA have agreed to an indication that would allow the firm to market its percutaneous Impella pumps for circulatory support of patients in cardiogenic shock following acute myocardial infarction or cardiac surgery, and no advisory panel will be needed before FDA makes an approval decision, the company says.
You may also be interested in...
Impella 2.5 PMA Gives Abiomed Big Growth Potential For High-Risk PCIs
The approval, the first for a percutaneous hemodynamic support device, frees Abiomed's hand to market the miniature blood pump to a relatively broad patient population, analysts note.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.